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Imaging Clinic
Medication-Related Osteonecrosis
of the Mandible
Galal Omami, BDS, MSc, MDentSc, FRCD(C)1
Medication-related osteonecrosis of the jaw (MRONJ) is a
pathologic process that rarely follows exposure to antire-
soptive agents such as bisphosphonate or denosumab,
which are used to treat lytic bone lesions in patients with
osseous metastases related to carcinoma of the breast or
prostate, multiple myeloma, Paget’s disease, and osteoporo-
sis. These drugs inhibit osteoclastic bone resorption and
remodeling.
The risk of osteonecrosis of the jaw in patients receiving
either bisphosphonate or denosumab ranges from 0.7% to
6.7%.1 However, this condition occurs more commonly in
patients receiving the medication intravenously and after a
surgical dental procedure, such as extraction or implant pla-
cement. The diagnosis of MRONJ is made clinically when
there is nonhealing exposed bone persisting for more than
8 weeks in a patient with current or previous treatment with
antiresorptive agents but without a history of radiation ther-
apy to the jaws.2
Radiologically, the bone can be normal in the early stages.
In advanced cases, a mixture of bone sclerosis and rarefaction
occurs. Bone sequestra are seen more commonly in the mand-
ible and often the sequestra appear as radiopaque islands of
bone in radiolucent regions (Figure 1). Large sequestrum may
weaken the bone and promote pathologic fracture. In contrast
to osteomyelitis, there is no periosteal bone reaction in most
cases.3
Magnetic resonance imaging can detect the early stage of
the disease. The bone marrow shows low signal intensity on
T1-weighted images and high signal intensity on T2-weighted
images.4
In patients with osteonecrosis of the jaw, regular preven-
tive dental care is of foremost importance.2 Conservative
treatments include maintaining good oral hygiene, eliminat-
ing sources of infection, and application of antimicrobial
mouth rinses. Because of the reduced healing capacity of
bone, surgical intervention should be limited to a minimal
debridement of the exposed necrotic bone. Systemic anti-
biotics and hyperbaric oxygen may be used as adjunctive
therapies.1,2
Figure 1. A 61-year-old woman with osteochemonecrosis of the
right mandible. The patient was treated with intravenous bispho-
sphonates for metastatic breast cancer. A, Cone beam computed
tomography (CT) reformatted thin-slice panoramic image shows large
region of bone destruction in the right body of the mandible with
diffuse sclerotic bone reaction and presence of multiple sequestra.
Axial (B) and coronal (C) cone beam CT images show increase in
density and size of the right mandible compared with the left side.
Arrows (B and C) point to a large sequestrum. There is no evidence
of periosteal bone formation.
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